There is no excerpt because this is a protected post.
Ibio (AMEX:IBIO) Price Movement From Ebola/Enterovirus Hype Ibio (AMEX:IBIO) ($1.47) is a leading provider of plant-based biotechnology for developing and manufacturing biological products. As expected, the hype surrounding the Ebola and Enterorvirus outbreaks in the U.S. will inevitably led to aggressive share price […]
22nd Century Group, Inc. (XXII) put out a press release this morning announcing that they have scheduled a meeting with the FDA to “discuss further development of the company’s potential modified risk tobacco product, code named BRAND B. It’s Really Only […]
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
22nd Century Group, Inc. (XXII) – Closed a $10 million private placement adding to dilution We will look to add to our short position. 22 days after trying to rebut our claims about the company’s share count rising, XXII Closed a $10 […]
Summary We offer a rebuttal to all four of XXII’s counterarguments to our piece published Wednesday (yesterday) morning. Rather than worry about the nuanced arguments XXII made in its rebuttal, we believe investors should be more interested in what XXII […]
While doing our research, we’ve noted a lot of company press releases that seem impressive on the surface, but that have all ultimately led to where the company is now-poised for more dilution and continually posting losses. When considering whether […]